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Abstract
In current clinical practice, Serum Creatinine (SCr) is a commonly used marker for the diagnosis of acute kidney
injury (AKI). Unfortunately, due to a delayed increase in SCr, it is unable to accurately estimate the timing of the
injury. The purpose of this study was to assess the ability of plasma neutrophil gelatinase-associated lipocalin
(pNGAL) to predict AKI in critically ill adult patients. The study was conducted at the Section of Chemical Pathology,
Department of Pathology& Laboratory Medicine in collaboration with Department of Anesthesiology, at Aga Khan
University Hospital in Karachi, Pakistan. Subjects in the age groups of18 to 60, that were admitted into the intensive
care unit (ICU) with suspected sepsis were enrolled in this study.AKI was labeled by using Risk-Injury-Failure-loss-End
Stage (RIFLE) criteria. Forty-eight patients, mean age being 46.5 ± 16.3, were recruited over a nine-month period.
Multiple blood samples were collected from each patient at 12 h, 24 h, and 48 h. A total of 52.1% (n = 24) of ICU
patients suspected of sepsis had developed AKI. Baseline characteristics of subjects with AKI were compared to
those without AKI. Statistically significant difference was noted in gender (p-value< 0.05) and pNGAL (p-value< 0.
001). However, no significant differences were seen with respect to age, in patients with and without AKI. The area
under the curve (AUC) at12hr was 0.82 (95% CI 0.68–0.96) with a sensitivity of 70.8% and specificity of 90.9%.While
AUCs at 24 h was 0.86(95% CI 0.74–0.97) with a sensitivity of 78.5% and specificity of 88.8%. Furthermore, there was
a positive correlation between pNGAL and the length of ICU stay (r = 0.98). Non-survivors or expired patients had
higher median pNGAL170 (202–117) ng/ml as compared to survivors 123(170–91) ng/ml. In conclusion, pNGAL is
an early predictor of AKI in a heterogeneous adult ICU population. Plasma NGAL allows the diagnosis of AKI 48 h
prior to a clinical diagnosis based on RIFLE criteria. Early identification of high-risk AKI in patients may allow earlier
initiation of therapies and improve patient outcome.
Keywords: Acute kidney injury (AKI), Sepsis, Plasma neutrophil gelatinase associated Lipocalin (pNGAL), Intensive
care unit (ICU)
Introduction
Acute kidney injury (AKI) is a rapid loss of kidney func-
tion following failure to maintain fluid, acid-balance, and
electrolyte homeostasis [1]. Acute kidney injury alone
complicates7.2 to 20% of hospitalized patients and 13–
78% of intensive care unit (ICU) patients [2–8]. Critic-
ally ill patients with concomitant AKI have a poor
prognosis and a high mortality rate. Sepsis is a common
cause of AKI in critically ill patients and various obser-
vational studies have found that sepsis contributes 30–
50% of all AKI cases [9].
In the last few decades, serum Creatinine (SCr) is used
for the diagnosis of AKI in common practice, but SCr is
a functional marker and not an ideal biomarker to iden-
tify AKI. The values of SCr are influenced by multiple
non-renal factors, like age, gender, muscle mass and me-
tabolism, dietary habits, medications, and hydration sta-
tus [9]. There is a considerable delay in increase of SCr
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after AKI and it does not reflect the actual decrease in
glomerular filtration rate (GFR). Additionally, SCr may
not rise until more than half of the kidney function has
been lost. Delay in prompt diagnosis and management
of AKI may cause irreversible kidney damage. RIFLE cri-
terion was proposed by Acute Dialysis Outcome Initiati-
ve(ADQI) group in order to have a uniform standard for
diagnosis and classification of AKI, including Risk(R), In-
jury (I), Failure (F), Loss (L), and End-Stage (E) renal dis-
ease as a tool for qualifying and quantifying the severity
of AKI [10]. The RIFLE based on either two-fold in-
crease in the SCr from baseline, or GFR decrease by
50%, or urine output < 0.5 ml/kg per hour for 12 h.
Many studies in the literature have applied SCr criteria
(RIFLE-SCr), but there are some inherent limitations.
First, it is based on relative changes in serum or plasma
Cr, due to varying extrarenal clearance; Cr is a late and
unreliable responder to GFR alterations. Second, Cr is a
small molecule (113 Da) and may pass through the
glomerular filter freely even when glomerular pores are
moderately narrowed [11]
There is a need for a reliable AKI biomarker, which
should be sensitive, specific, depict early change follow-
ing kidney injury, easy to measure, and does not require
administration of an exogenous substance. Many new
promising AKI biomarkers have been identified and one
such promising biomarker is plasma Neutrophil
Gelatinase-Associated Lipocalin (pNGAL) [12]. Numer-
ous studies have been done on this biomarker, but it is
still controversial to use this biomarker in the clinical
setting as an AKI marker. Metanalysis done by An
Zhang and his colleagues (2016) stated that” Utility of
NGAL to predict the occurrence of AKI in septic pa-
tients remains controversial” [13]. Therefore, the object-
ive of this study is to assess the ability of pNGAL to
predict early AKI in critically ill adult patients presenting
with sepsis.
Material and methods
Patient recruitment
A cross-sectional study was conducted at the Section of
Chemical Pathology, Department of Pathology & La-
boratory Medicine in collaboration with the Department
of Anesthesiology at Aga Khan University Hospital in
Karachi, Pakistan during December 2014 to August
2015. Patient clinical details along with demographics
and relevant biochemical data were recorded on a struc-
tured proforma within 12 h of admission to intensive
care unit (ICU).
Inclusion criterion
All subjects that are between the ages of 18–60, admit-
ted to the ICU at Aga Khan University Hospital with
suspected sepsis were included in the study. Sepsis was
defined as per systemic inflammatory response syn-
drome (SIRS) criterion if patients presented with: body
temperature > 38 °C (100.4 °F) or < 36 °C (96.8 °F),heart
rate > 90 beats per minute, respiratory rate > 20 breaths
per minute or arterial carbon dioxide tension (PaCO 2)
< 32mmHg, Abnormal white blood cell count (> 12,000/
μL or < 4000/μL or > 10% immature and white blood cell
count > 12,000 × 10 [8]/L or < 4000 × 10 [8]/L. [11, 12]
Prediction of AKI and calculation of baseline serum
creatinine
Using Risk-Injury-Failure-Loss-End Stage (RIFLE-SCr)
proposed by the Acute Dialysis Quality Initiative (ADQI)
group [14]. A twofold increase in SCr from baseline
value was considered as AKI [15]. Cut off 150 ng/ml of
Plasma NGAL used for the Prediction of Acute kidney
injury [13, 16].
Patient’s baseline serum Creatinine (bSCr) levels were
calculated by using the Modification of Diet in Renal
Disease (MDRD) equation proposed by the Acute Dialy-
sis Quality Initiative (ADQI) working group by using
formula [17]:
Serum Creatinine = (75/186× (age− 0.203) × (0.742 if fe-
male) × (1.21 if black)]) − 0.887
Exclusion criterion
Pregnant females, patients with known chronic kidney
disease, patients on hemodialysis, renal transplant recipi-
ents, and those with known kidney malignancy were ex-
cluded. Death of patients or early ICU discharged
patients was also excluded from this study.
Blood sampling and biochemical analysis
Serial blood sampling was done for pNGAL in the fol-
lowing manner: first within 12 h of admission to ICU,
second after 24 h, and a third sample was drawn after
48 h of the first sample. Three to four milliliters of blood
was drawn each time in ethylenediaminetetraacetic-acid
(EDTA) vacuutainer. Blood samples were centrifuged at
3000 rpm for 15min, aliquoted (for what> be specific),
and stored at − 80 °C until analysis. The pNGAL was an-
alyzed by fluorescence immunoassay on Triage® Meter
Proby Alere Diagnostics point of care analyzer, CA, US.
Two levels of manufacturer-provided quality controls
(low and high) were run with each batch of analysis.
Statistical analysis
Data was analyzed using the Statistical Package for the
Social Sciences (SPSS version 19.0). Frequency and per-
centages were calculated for gender. Mean, standard de-
viation, and median with interquartile ranges was
computed for a continuous variable, the age of the pa-
tients, duration of hospital stay, and pNGAL. The
pNGAL levels between patients with and without AKI
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were compared by independent t-test. The diagnostic ac-
curacy of pNGAL to predict AKI in critically ill patients
of ICU was assessed by applying Receiver Operator
Curve (ROC) analysis and calculating the area under the
curve (AUC) at 24 and 48 h. A p-value of < 0.05 was
considered as statistically significant.
Results
In this prospective study, adult patients admitted into
the ICU with suspicion of sepsis were recruited over a
period of nine months. However, two of the 48 patients
expired before blood sampling was completed. Forty-six
patients fulfilled the criteria for sepsis and were sub-
jected to blood sampling and biomarker analysis (Fig. 1).
The mean age of patients (n = 46) was 46.5 ± 16.3 years
with the majority being males. Mean BMI of the patients
was 26.2 ± 4.8 kg/m [9]. Baseline mean SCr of males and
females was 1.1 ± 0.1 mg/dl and 0.8 ± 0.7 mg/dl respect-
ively. Table 1 describes the general characteristics and
clinical details of the study group. Median ICU stay of
the study group was 6 days (4–13 days).
Plasma NGAL levels increased by 41.3%(n = 19) at 12
h, 50%(n = 23) at 24 h and 54.3%(n = 25) at 48 h of ICU
admission. Using RIFLE criteria, a total of 52.1% (n = 24)
of ICU patients developed AKI during their ICU stay.
Out of these pNGAL levels increased by 70.8%(n = 17) at
12 h of ICU admission and 79%(n = 19) patients at 24 h
of ICU admission. However, 5 patients were mislabeled
by pNGAL as AKI. SCr reached endpoint at 48 h of ICU
stay with median SCr was 2.3(3.1–2.1) mg/dl at 48 h of
ICU admission.
Baseline characteristics of subjects with AKI were
compared with those without AKI. Statistically, a signifi-
cant difference was noted in gender (pvalue< 0.05) and
pNGAL (value< 0.001) between patients with (Fig. 2)
and without AKI (Table 2). However, no significant dif-
ferences were seen in age, between patients with and
without AKI. AUCs at12 hours was 0.82 (95%CI 0.68–
0.96) with sensitivity of 70.8% and specificity of 90.9%.
AUCs at 24 h was 0.86(95%CI 0.74–0.97) with the sensi-
tivity of 78.5% and specificity of 88.8%. There was a posi-
tive correlation between pNGAL and the duration of the
ICU stay (r = 0.98). Mortality rate was 32.6% (n = 15),
while 67.3%(n = 31) of patients were shifted to the wards
48 patients fulfilled the eligibility criteria
46 patients with sepsis enrolled in the study
No evidence of AKI, n=22
Alive, n=18 Deceased, n =4
AKI during ICU stay, n=24
Alive, n=13 Deceased, n =11
2 patients expired before sample 
completion
Fig. 1 Profile of recruitment and outcome of study group
Table 1 Demographics and clinical details of patients (n = 46)
admitted to ICU with sepsis
Characteristics n (%)
Males n (%) 32 (69%)
Stratification of subjects as per WHO classification
Normal 16 34.8%)
Overweight 23 (50%)
Obese 7 (15.2%)
Comorbids
No Comorbids 20 (43.5%)
DM, HTN and Cardiovascular Disease 16 (32.6%)
Cardiovascular Disease 3 (6.5%)
DM 2 (4.3%)
Pulmonary Disease 2 (4.3%)
Liver Disease 2 (4.3%)
Malignancy 1 (2.2)
Abbreviations: intensive care unit, ICU basal metabolic index, BMI diabetes
mellitus, DM hypertension, HTN
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from the ICU. Amongst expired patients12hour median
pNGAL was 170(202–117) ng/ml as compared to survi-
vors which were 123(170–91) ng/ml.
Discussion
The utilization of pNGAL for the prediction of AKI
was studied. All patients that were admitted with
suspected sepsis not having AKI on admission were
used as the study subjects to analyze p NGAL for the
prediction of AKI. It was observed that pNGAL levels
were significantly higher in patients who developed
AKI in comparison who did not develop AKI
(p-value< 0.05).This allowed to distinguish AKI pa-
tients from non-AKI patients. A similar study per-
formed by Soto and his colleagues (2013), stated that
highest median levels of pNGAL seen in patients with
AKI (146–174 ng/ml at various points) increased level
with AKI severity (207–244 ng/ml) [18]. Another study
performed by Usman et al. in 2013 also reported nearly
similar median (IQR) of pNGAL of 170 ng/ml (126–274
ng/ml) in patients who develop AKI [19]
There is no consensus about the cutoff value of
pNGAL at which AKI diagnosis can be made accurately
[20].We used a cutoff of 150 ng/ ml to predict AKI,
which was similar cutoff used by Camou et al. in 2013
[16] and Wang et al. [21] in 2014 to predict AKI. A sys-
tematic review and meta-analysis done by Zhang et al.
[13] which included the studies of Yamashita et al. [22]
and Dai et al. [23] reported diagnostic ability of pNGAL
with AUCs of 0.94 (95% CI, 0.88–0.97) and 0.92 (95%
CI, 0.84–0.96) respectively for plasma NGAL to predict
AKI in septic patients similar to our findings. Azrina
ralib et al. reported similar AUC for pNGAL for the
diagnosis of AKI, 0.81 (95%CI 0.74 to 0.87) [24].
NGAL was originally isolated from secondary granules
of human neutrophils as a 25 KDa protein covalently
linked to matrix metalloproteinase-9 (MMP-9) in human
neutrophils [25]. It is highly induced proteins in the
Fig. 2 ROC curve of pNGAL at the 12 and 24 h time points
Table 2 Biochemical characteristics of patients with and without AKI
Variables Patients with suspected sepsis (n = 46) p-value
AKI
n = 24
Non-AKI
n = 22
Male n (%) 18 (39.1%) 14 (30%) < 0.05
Mean WBC count × 10 [8] 16.0 ± 7.1 16.7 ± 6.3 > 0.05
Median pNGAL at 12 h (ng/ml) 185 (262–142) 110 (120–70) < 0.05
Median pNGAL at 24 h (ng/ml) 400 (585–185) 130 (145–80) < 0.05
Median pNGAL at 48 h (ng/ml) 597 (452–1050) 133 (140–60) < 0.05
Non-Survivors 11 (45.8%) 4 (16.6%) > 0.05
Quantitative variables are expressed in mean ± SD or median (IQR) and frequencies as n (%). Abbreviations: acute kidney injury, AKI Plasma neutrophil Gelatinase
associated Lipocalin, pNGAL, SerumCreatinine, Scr
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kidney after ischemic or nephrotoxic AKI in animal
models [26]. Its levels can be detected in the plasma of
patients as early as 2 h, peak at approximately 6 h after
injury and its levels remain elevated for as long as five
days, after which they begin to decrease [18].
The study has several limitations as it was conducted
at a single center with a small sample size and a strict
inclusion criterion of patients with SIRS. PNGAL was
measured within 12 h of ICU admission; however
measurement within 2–4 h may capture earlier changes
that occur with kidney injury. However, it has been ob-
served that there were no differences in NGAL perform-
ance when measured earlier within the ED or later in
the ICU. A previous study, show plasma NGAL level,
especially within 12 h of ICU admission, is an early and
accurate predictor of AKI.
Conclusion
High plasma NGAL levels noted within 12 h of ICU ad-
mission allows AKI diagnosis 48 h prior to the diagnosis
based on RIFLE criteria and proves to be an early and
accurate predictor of AKI. It can be utilized as an early
biomarker for the detection of AKI in critically ill pa-
tients with sepsis in ICU so that potentially beneficial
therapies can be initiated before irreversible kidney in-
jury occurs.
Abbreviations
AKI: Acute Kidney Injury; ARF: Acute Renal Failure; ATN: Acute tubular
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